4th Annual Pharma Regulatory Summit 2021 (Virtual Conference)
4th Annual Pharma Regulatory Summit 2021
18th March 2021, Virtual Conference (Time Zone - IST)
Greetings from Virtue Insight,
Join 4th Annual Pharma Regulatory Summit 2021 virtual conference and engage in a series of strategic discussions on current regulatory landscape, globalization, and harmonization initiatives in India. Virtue Insight brings you an interactive dynamics, where you will be engaged in discussions with key stakeholders influencing the advancement and implementation of regulatory convergence initiatives. Join us to discuss multi-regional cooperation, global harmonization, and best practices related to India’s regulatory landscape. Sessions will highlight regulatory approaches and good practices to ensure certainty in India and strategic initiatives to improve collaboration and cooperation.
E-mail - firstname.lastname@example.org or Call M: +91 9940791115
Please note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer.
- Early Bird Price (Till 2nd February 2021) – (INR 6,000 + GST (18%) per delegate)
- Standard Price (From 3rd February 2021) – (INR 8,000 + GST (18%) per delegate)
- For more than 5 delegates please let us know your interests.
Conference Sponsor, Exhibition Stall & Paid Speaker Slot - Please email your interest and queries to email@example.com
- RAJENDRA SANGHAVI, Sr. Consulting Clinician / Expert - MedicoMarketing & TechnoLegal (Healthcare) / Chairman - Nutraceutical Committee, (IDMA)
- SADHNA JOGLEKAR, Senior Vice President, Global Medical Affairs, Sun pharma
- YASMIN SHENOY, Director-Regulatory Affairs, Sanofi-aventis
- RAHUL GUPTA, Vice President, Regulatory Affairs, USV
- PRATIK SHAH, Vice President - Medical Affairs, Bharat Serums and Vaccines
- RASHMI HEGDE, Vice President Medical, Cipla
- DEEPA ARORA, Director, CLINEXEL Life Sciences
- MILIND NARVEKAR, Vice President Global Regulatory Affairs, Teva Pharmaceuticals
- SHARADD JAIN, Vice President, Cipla
- ASHISH GAWDE, Country Medical Director, Bayer Pharmaceuticals
- AMEY MANE, Director-Medical Affairs, Dr. Reddy’s Laboratories
- SHIRAZ KANDAWALLA, Associate Director - Regulatory Affairs, Abbott
- DILIP PAWAR, Global Head Medical Affairs and Pharmacovigilance, Unichem Laboratories
- ARIF KHAN, Head – Regulatory Affairs, Pharmacovigilance and Medical Information, UCB
- SANDEEP ARORA, Medical Affairs Head, Takeda
- NANDAN JOSHI, Head Medical Affairs - Nutrition, India and Emerging Markets, Dr. Reddy's Laboratories
- HARSHAD KOTHAWADE, Head of Regulatory Management & Trade Compliance, Merck group
- MINOO BIJU, Head-Regulatory Affairs, Piramal Pharma Solutions
- SANJEEV KUMAR, Head- Regulatory External Manufacturing, Sanofi
- AMITA BHAVE, Head Regulatory Affairs GDD India, Novartis
- MANISH MAHAJAN, Head- Medical Affairs, Cadila Healthcare (BU- Biologics)
- SOFI JOSEPH, Head of Regulatory Affairs and Pharmacovigilance, Serdia Pharmaceuticals
- VARSHA NARAYANAN, Founder-Director & Senior Consultant Medical Affairs, Dr Varsha’s Health Solutions
- VISHWAS SOVANI, Founder Director, Pharmawisdom
Plus more joining soon
KEY THEMES DISCUSSED:
- Assure access to medications: How will regulatory weaknesses in pharmaceuticals be addressed?
- Political landscape: how could medical policy be affected?
- Addressing political mechanisms and advantages intended to regulate the business.
- Present regulatory system for the growth and effective production of medicinal products in scientific and technological ways
- Discussing how to ensure operational performance in compliance with the aim of better regulation.
- Regulatory and consumer opportunities for patients to approve and retain critical drugs
- Addressing existing problems in the growth of more complex off-patent medicinal products
- Regulatory structure for complex off-patent drugs, from the viewpoint of global product growth
- Regulatory challenges for medical devices
- Discussing the efficiency of the devices and regulatory initiatives
- Priorities of new Indian Commission's policies relevant to pharmaceuticals
- Addressing the Indian System of Medicine's acceptance of the new medical science by health personnel.
- Real word evidence: How it could be used to facilitate regulatory decision-making
- Addressing patient's health and health care delivery data that are regularly obtained from a number of sources
- Possible legislative options to help minimise the risk of shortages and to reduce them
- Addressing the problem as well as other supply chain issues
- Initiatives of regulatory convergence – How the regulators and stakeholders of medical products may benefit from the guidance and convergence activities in India.
- Guidelines for national regulatory authorities for medical products
- Be part of a major networking opportunity
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition.